Safety and efficacy of locoregional therapy for metastatic pancreatic ductal adenocarcinoma to the liver: a single-center experience | Zendy

Ryan E. Bailey | Zendy; Phani Keerthi Surapaneni | Zendy; Jacob Core | Zendy; Lucas Lauar Cortizo Vidal | Zendy; Jordan D. LeGout | Zendy; Charles Ritchie | Zendy; G. Frey | Zendy; J. Mark McKinney | Zendy; David M. Sella | Zendy; Ricardo PazFumagalli | Zendy; Beau Toskich | Zendy; Kabir Mody | Zendy

Open Access

Safety and efficacy of locoregional therapy for metastatic pancreatic ductal adenocarcinoma to the liver: a single-center experience

Author(s) -

Ryan E. Bailey,

Phani Keerthi Surapaneni,

Jacob Core,

Lucas Lauar Cortizo Vidal,

Jordan D. LeGout,

Charles Ritchie,

G. Frey,

J. Mark McKinney,

David M. Sella,

Ricardo PazFumagalli,

Beau Toskich,

Kabir Mody

Publication year - 2019

Publication title -

journal of gastrointestinal oncology

Language(s) - English

Resource type - Journals

eISSN - 2219-679X

pISSN - 2078-6891

DOI - 10.21037/jgo.2019.03.13

Subject(s) - medicine , response evaluation criteria in solid tumors , adverse effect , single center , progressive disease , stage (stratigraphy) , chemotherapy , pancreatic ductal adenocarcinoma , oncology , pancreatic cancer , surgery , radiology , gastroenterology , cancer , paleontology , biology

Many patients with pancreatic ductal adenocarcinoma (PDAC) are diagnosed with liver metastatic disease (mPDAC), and few are surgical candidates. Interventional oncology (IO) locoregional therapies (LRT) have proven beneficial in other primary and metastatic hepatic malignancies. Systemic chemotherapy is the standard of care for patients with mPDAC. This study assessed the safety and efficacy of LRT including thermal ablation, chemoembolization, and radioembolization for mPDAC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research